image
Healthcare - Medical - Instruments & Supplies - NYSE - CH
$ 92.38
0.065 %
$ 45.6 B
Market Cap
39.48
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one ALC stock under the worst case scenario is HIDDEN Compared to the current market price of 92.4 USD, Alcon Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one ALC stock under the base case scenario is HIDDEN Compared to the current market price of 92.4 USD, Alcon Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one ALC stock under the best case scenario is HIDDEN Compared to the current market price of 92.4 USD, Alcon Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
9.46 B REVENUE
8.47%
1.04 B OPERATING INCOME
54.61%
1.04 B NET INCOME
210.33%
1.48 B OPERATING CASH FLOW
21.73%
-1.09 B INVESTING CASH FLOW
41.34%
-211 M FINANCING CASH FLOW
-2537.50%
2.45 B REVENUE
-2.28%
332 M OPERATING INCOME
4.40%
223 M NET INCOME
-10.08%
530 M OPERATING CASH FLOW
55.43%
-133 M INVESTING CASH FLOW
38.99%
-171 M FINANCING CASH FLOW
-159.09%
Balance Sheet Alcon Inc.
image
Current Assets 5.65 B
Cash & Short-Term Investments 1.1 B
Receivables 1.98 B
Other Current Assets 2.56 B
Non-Current Assets 24 B
Long-Term Investments 319 M
PP&E 4.72 B
Other Non-Current Assets 18.9 B
Current Liabilities 2.48 B
Accounts Payable 811 M
Short-Term Debt 216 M
Other Current Liabilities 1.45 B
Non-Current Liabilities 6.51 B
Long-Term Debt 4.93 B
Other Non-Current Liabilities 1.58 B
EFFICIENCY
Earnings Waterfall Alcon Inc.
image
Revenue 9.46 B
Cost Of Revenue 4.21 B
Gross Profit 5.25 B
Operating Expenses 4.21 B
Operating Income 1.04 B
Other Expenses -613 K
Net Income 1.04 B
RATIOS
55.49% GROSS MARGIN
55.49%
10.99% OPERATING MARGIN
10.99%
10.30% NET MARGIN
10.30%
4.72% ROE
4.72%
3.29% ROA
3.29%
4.45% ROIC
4.45%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Alcon Inc.
image
Net Income 1.04 B
Depreciation & Amortization 1.3 B
Capital Expenditures -851 M
Stock-Based Compensation 144 M
Change in Working Capital -431 M
Others -402 M
Free Cash Flow 537 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Alcon Inc.
image
Wall Street analysts predict an average 1-year price target for ALC of $102 , with forecasts ranging from a low of $85 to a high of $110 .
ALC Lowest Price Target Wall Street Target
85 USD -7.99%
ALC Average Price Target Wall Street Target
102 USD 9.87%
ALC Highest Price Target Wall Street Target
110 USD 19.07%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.264 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Alcon Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Algoma Central Corporation Announces a 5% Increase in Quarterly Dividend ST. CATHARINES, Ontario--(BUSINESS WIRE)-- #yourmarinecarrierofchoice--Algoma Central Corporation (“Algoma” or “the Company”) (TSX: ALC), a leading provider of marine transportation services, today announced that the Company's Board of Directors authorized payment of a quarterly dividend to shareholders of $0.20 per common share. The dividend is payable on March 3, 2025 to shareholders of record on February 14, 2025. This $0.20 common share dividend represents a 5% increase from the $0.19 per share dividend paid on Decembe. businesswire.com - 2 weeks ago
Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference GENEVA--(BUSINESS WIRE)--Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference. businesswire.com - 1 month ago
Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference GENEVA--(BUSINESS WIRE)--Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference. businesswire.com - 1 month ago
Here's Why Alcon (ALC) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 1 month ago
RxSight downgraded to Hold from Buy at Stifel Stifel downgraded RxSight (RXST) to Hold from Buy with a price target of $40, down from $65. The firm's latest deep-dive survey of surgeons leads to believe that the risk from U.S. premium IOL - intraocular lens - competition may be more material than investors appreciate, with JNJ's (JNJ) new Tecnis Odyssey lens "jumping off the page" in its findings and with Alcon's (ALC) PanOptix Pro around the corner, the analyst tells investors in a research note. Stifel adds that its longitudinal analysis shows the respondents' 2025 LAL - light adjustable lenses - volume expectations are moderately weakening, giving the firm pause around the intermediate-term LAL path ahead. RxSight +1.02 (+2.74%) Johnson & Johnson -1.16 (-0.80%) Alcon -0.56 (-0.66%) https://thefly.com - 1 month ago
Needham ups Alcon target, adds to Conviction List Needham earlier today raised the firm's price target on Alcon (ALC) to $108 from $103 and kept a Buy rating on the shares. The firm also added the stock to its Conviction List, replacing RxSight (RXST). Alcon's product launch lineup is one of the best it's been since its spin from Novartis, the analyst told investors in a research note. Needham expects the product launches to result in Alcon's revenue growth accelerating throughout 2025, which should drive multiple expansion. The firm made the stock a top pick for 2025. With the stock's valuation meaningfully below Alcon's historical range, risks around currency and commercial investments are baked in, making the risk/reward attractive, contended Needham. Alcon +1.88 (+2.24%) RxSight -0.1 (-0.26%) https://thefly.com - 1 month ago
Reasons to Retain Alcon Stock in Your Portfolio for Now Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC. zacks.com - 1 month ago
Why Alcon (ALC) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 1 month ago
Alcon (ALC) is a Top-Ranked Value Stock: Should You Buy? The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 2 months ago
Alcon: Q3, Slight Guidance Cut Is Not Something Structural I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $118 per share, despite a minor guidance cut. Alcon's new product launches, including PRECISION7 and Systane Pro, are expected to drive significant growth in the vision segment. Alcon's surgical business, with a strong position in cataract surgery, is projected to grow 7% annually, driven by advanced technology and international expansion. seekingalpha.com - 2 months ago
Alcon (ALC) Q3 2024 Earnings Call Transcript Alcon Inc. (NYSE:ALC ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Dan Cravens - Vice President, Investor Relations Conference Call Participants Graham Doyle - UBS Jack Reynolds-Clark - RBC Capital Markets David Saxon - Needham & Co. Larry Biegelsen - Wells Fargo Patrick Wood - Morgan Stanley Ryan Zimmerman - BTIG Jeff Johnson - Baird Anthony Petrone - Mizuho Tom Stephan - Stifel Brett Fishbin - Keybanc Capital Markets David Adlington - JP Morgan Giang Nguyen - Citi Issie Kirby - Redburn Atlantic Sajid Aznar - HSBC Falco Freidrichs - Deutsche Bank Operator Greetings and welcome to the Alcon third quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. seekingalpha.com - 2 months ago
Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours ALC's performance is driven by robust demand for the company's innovative products, balanced geographic footprint and strong execution by the team. zacks.com - 2 months ago
8. Profile Summary

Alcon Inc. ALC

image
COUNTRY CH
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 45.6 B
Dividend Yield 0.00%
Description Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Contact Chemin de Blandonnet 8, Geneva, 1214 https://www.alcon.com
IPO Date April 9, 2019
Employees 25000
Officers Mr. Timothy C. Stonesifer Senior Vice President & Chief Financial Officer Margaret Buckley Chief Accounting Officer Mr. Arthur B. Cummings M.D. Executive Director Dr. Franck Leveiller SVice President of Global Research & Development and Chief Scientific Officer Ms. Kimberly Martin Senior Vice President, Chief HR Officer & Corporate Communications Mr. David J. Endicott Chief Executive Officer & Director Mr. Royce R. Bedward J.D. Senior Vice President, General Counsel & Corporate Secretary Mr. Muru Murugappan Senior Vice President and Chief Information & Transformation Officer Mr. F. Michael Ball Executive Chairman Mr. Ian Bell Senior Vice President & Chief Operating Officer